What RVL Pharmaceuticals does

RVL Pharmaceuticals is a US-based specialty pharmaceutical company that develops and commercializes prescription and consumer products at the intersection of eye care and medical aesthetics. Its flagship asset is Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved prescription eye drop for acquired blepharoptosis (low-lying eyelids) in adults, approved in July 2020. The product activates a muscle in the eyelid to produce a visible lift in as fast as five minutes that lasts up to eight hours, positioning it as a non-surgical alternative to eyelid surgery. The company has since expanded its portfolio with Upneeq Reveal Under Eye Complex, an OTC skincare product launched in 2026 and priced at $75 per 15mL, and has licensed UPNEEQ Mini to Santen Pharmaceutical for development, registration, and commercialization in Japan and certain other international markets, where it received manufacturing and marketing approval in January 2026.

RVL operates a vertically integrated omnichannel commercial platform that combines a direct-to-consumer telehealth channel on Upneeq.com, a wholly-owned mail-order pharmacy subsidiary for prescription fulfillment, a monthly auto-refill subscription program, and a separate healthcare provider channel supported by the Meet UPNEEQ provider app. The business is cash-pay at the consumer level — Upneeq is not covered or reimbursed by federal or state healthcare programs — and is supported by multichannel digital and performance marketing, including a flagship brand partnership with Cindy Crawford. The company is privately held, with Athyrium Capital Management serving as the majority shareholder and board chair; it was formerly known as Osmotica Pharmaceuticals plc prior to rebranding as RVL Pharmaceuticals, Inc. The company is headquartered in Bridgewater, New Jersey, employs 101-250 people, and recently installed Lori Deo as CEO and Amy Shah as Chief Growth Officer to scale its commercial organization.

Name

RVL Pharmaceuticals

Legal name

RVL Pharmaceuticals, Inc.

Website

https://rvlpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

RVL Pharmaceuticals is a US specialty pharma company that develops and commercializes Upneeq, the first and only FDA-approved prescription eye drop for acquired blepharoptosis, serving adult patients, prescribers, and aesthetic consumers through vertically integrated telehealth, mail-order pharmacy, and subscription channels.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Prescription eye drops
• Ophthalmic pharmaceuticals
• Aesthetic eye care
• Blepharoptosis treatment
• Under-eye skincare

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

1. Upneeq® Prescription Product Sales: Revenue generated from prescription sales of Upneeq®, the FDA-approved prescription eye drop for acquired blepharoptosis. Sold on a cash basis directly to consumers who obtain prescriptions through healthcare providers or telehealth platform. The company operates its own mail-order pharmacy including a subsidiary pharmacy to fulfill prescriptions.
2. Upneeq Reveal™ Skincare Sales: Direct-to-consumer sales of the Upneeq Reveal™ Under Eye Complex skincare product. Sold through UpneeqReveal.com at $75 for 15mL.
3. Licensing Royalties: Exclusive license agreement with Santen covering development, registration, and commercialization rights for the oxymetazoline hydrochloride ophthalmic solution product in Japan and certain other international markets. Santen obtained manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

RVL Pharmaceuticals develops and commercializes Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved prescription eye drop for acquired blepharoptosis (low-lying eyelids), sold via a vertically integrated DTC telehealth and HCP channel. The company has expanded into OTC skincare with Upneeq Reveal™ Under Eye Complex, addressing dark circles, fine lines, and puffiness.

Product overview

RVL Pharmaceuticals operates a vertically integrated omnichannel commercial platform centered on its flagship prescription product Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved prescription eye drop for acquired blepharoptosis. The company has expanded into the OTC skincare segment with Upneeq Reveal™ Under Eye Complex. The platform combines direct-to-consumer telecommerce with healthcare provider channels to drive demand creation and streamline patient and prescriber engagement.

Differentiator

Problem solved

Functional benefit

Brands

• Upneeq: FDA-approved prescription eye drop treatment for acquired blepharoptosis (low-lying eyelids), containing oxymetazoline hydrochloride ophthalmic solution 0.1%.
• Upneeq Reveal

Products and services

• Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% FDA-approved prescription eye drop for acquired blepharoptosis (low-lying eyelids) in adults. Activates a muscle in the eyelids to provide a non-surgical eyelift with visible results in as fast as 5 minutes and effects lasting up to 8 hours. Sold on a cash basis directly to consumers who obtain prescriptions through healthcare providers or the Upneeq.com telehealth platform, with fulfillment via the RVL mail-order pharmacy.
• Upneeq Reveal™ Under Eye Complex Over-the-counter under-eye skincare treatment formulated with 5% stabilized Vitamin C, peptides, caffeine, creatine, and green tea actives. Brightens, firms, and smooths the under-eye area; addresses dark circles, fine lines, and puffiness. Sold directly to consumers through UpneeqReveal.com at $75 for 15mL, and dermatologist and ophthalmologist tested.
• UPNEEQ® Mini Ophthalmic Solution 0.1% (Japan) Japan-market variant of UPNEEQ® Mini Ophthalmic Solution 0.1% (oxymetazoline hydrochloride; development code STN1013800), manufactured and marketed by Santen Pharmaceutical under an exclusive license from RVL for acquired blepharoptosis.

Quantifiable outcome

• Visible results in as fast as 5 minutes
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Cindy CrawfordflagshipGTM or Marketing Partner · 27 May 2026Marketing partnership with supermodel and cultural icon Cindy Crawford for Upneeq® prescription eye drop treatment. Cindy Crawford is portrayed as a longtime user of the product, bringing personal experience to the partnership. Multichannel campaign spanning digital and social platforms alongside healthcare professional outreach, promoting themes of presence and confidence associated with eye aesthetics.
• Ron RobinsoncoreStrategic or Co-development Partner · 1 May 2026Veteran cosmetic chemist and product development expert who collaborated with RVL Pharmaceuticals to develop the Upneeq Reveal™ Under Eye Complex formula. Brings cosmetic formulation expertise to the product development process.
• Dr. Raymond DouglascoreStrategic or Co-development Partner · 1 May 2026Board-certified reconstructive oculoplastic surgeon and RVL Pharmaceuticals Head of Scientific Affairs. Endorsed the Upneeq Reveal™ Under Eye Complex, providing clinical insight into the product. Also serves as key opinion leader for the company.
• Santen Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 8 January 2026Exclusive license agreement covering development, registration, and commercialization rights for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution 0.1%) in Japan and certain other international markets. Santen obtained manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (development code: STN1013800) for treatment of acquired blepharoptosis. This represents the first non-invasive treatment approved for this condition in Japan, where options were previously limited to surgical procedures.

Scale indicators4 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Revance Therapeutics: Specialty aesthetics pharmaceutical company with a cash-pay DTC and physician-channel model for ophthalmology-adjacent and facial injectable products. Closely comparable in business model, prescriber base, and aesthetic-medicine positioning to RVL.
• Horizon Therapeutics (Amgen): Specialty pharmaceutical company built around a small number of high-value, narrowly-indicated therapeutics with focused physician promotion. Highly comparable go-to-market model and specialty pharma operating playbook to RVL.
• Supernus Pharmaceuticals: Mid-sized specialty pharmaceutical company focused on CNS with branded specialty products promoted through specialty physician channels. Comparable in the specialty pharma commercial model and small-cap public/private profile.
• Evolus: Aesthetics specialty pharma behind Jeuveau (prabotulinumtoxinA), competing in the cash-pay aesthetic injectables market. Direct analog to RVL's model of selling through aesthetic providers and DTC channels.

Broad incumbents

• Alcon: Global ophthalmology leader in surgical, vision care, and ophthalmic pharmaceuticals. Comparable as an established ophthalmic pharma incumbent, though significantly larger and more diversified.
• Galderma: Global dermatology and aesthetics pharmaceutical company with prescription, OTC, and skincare franchises (e.g., Restylane, Sculptra, Cetaphil). Comparable in the dermatology/aesthetics specialty pharma category and skincare adjacency.
• AbbVie (Allergan Aesthetics): Owner of the Botox franchise and broader aesthetics portfolio (Botox, CoolSculpting, SkinMedica). Comparable as the dominant aesthetic pharmaceutical incumbent against which Upneeq and Upneeq Reveal compete for physician mindshare and patient wallet share.
• Bausch + Lomb: Global ophthalmology company with pharmaceutical, surgical, and consumer eye care products. Comparable in ophthalmic pharmaceutical development and commercialization, though much broader in scope.

Others

• SkinMedica (Allergan/AbbVie): Professional skincare brand with dermatologist-grade product lines targeting similar under-eye and anti-aging concerns as Upneeq Reveal. Comparable as a direct competitor in the skincare channel extension RVL is pursuing.

Regional players

• Santen Pharmaceutical: Japan-based global ophthalmology specialty pharmaceutical company and RVL's exclusive licensee for UPNEEQ in Japan and certain other markets. Highly comparable in ophthalmology franchise focus and acts as both a partner and a regional peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/rvlpharma
• LinkedInlinkedin.com/company/rvl-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RVL Pharmaceuticals